Where is Oncoparse located?

Oncoparse is headquartered in Melbourne, Australia.

Who is the current CEO of Oncoparse?

Martin Thompson of Oncoparse. They have also founded 1 company.

Where does Oncoparse rank among its competitors?

Oncoparse ranks 117th amongst 115 active competitors, of which 35 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Lucida Medical, which secured $11.5M in Mar, 2026.

Who are the top competitors of Oncoparse?

Oncoparse's top competitors include Scholar Rock, Lucida Medical and SamanTree Medical. Among them, Lucida Medical secured the most recent funding round in March, 2026.

Oncoparse - 2026 Company Profile, Team & Competitors

Oncoparse is an unfunded company based in Melbourne (Australia), founded by Martin Thompson. It operates as a Developer of a non-invasive pancreatic cancer diagnostic tool. Oncoparse has not raised any funding yet. The company has 115 active competitors, including 35 funded and 9 that have exited. Its top competitors include companies like Scholar Rock, Lucida Medical and SamanTree Medical.

Company Details

Developer of a non-invasive pancreatic cancer diagnostic tool. This tool leverages circulating tumor DNA (ctDNA) and advanced sequencing technologies to provide clinicians with rapid and actionable genetic and epigenetic insights. The proprietary algorithms enable personalized treatment decisions, aiming to improve patient outcomes and survival rates. The diagnostic solution supports clinicians in early detection and effective management of pancreatic cancer.

Key Metrics

Location

Melbourne, Australia

Stage

Unfunded

Ranked

117^th among 134 competitors

Similar Companies

Lucida Medical & 106 more

View Oncoparse's full profile

Oncoparse has not raised any funding rounds yet.

The founders of Oncoparse is Martin Thompson. Martin Thompson is the CEO of Oncoparse.

Here are the details of Oncoparse's key team members:

Martin Thompson: CEO, Co-Founder of Oncoparse.

View details of Oncoparse's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Oncoparse include Scholar Rock, Lucida Medical and SamanTree Medical. Here is the list of Top 10 competitors of Oncoparse, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Scholar Rock 2012, Cambridge (United States), Public	Developer of Antibody-based drugs for the treatment of primary myopathies	$103M	Fidelity Investments, Invus & 10 others	61/100
2nd	Lucida Medical 2019, Cambridge (United Kingdom), Series A	Developer of MRI-based cancer screening technology using artificial intelligence (AI)	$11.5M	prostate-cancer-research.org.uk, IW Capital ... & 23 others	60/100
3rd	SamanTree Medical 2014, Lausanne (Switzerland), Series C	Developer of digital microscopy system for high-resolution imaging of tissue	$57.5M	European Investment Bank, Panakes Partners ... & 14 others	59/100
4th	Sysmex 1968, Kobe (Japan), Public	Developer of diagnostic instruments, reagents, and related software	-	-	55/100
5th	Ionpath 2014, Menlo Park (United States), Series B	Developer of an imaging platform for tissue biopsies	$18M	Samsara BioCapital, Agile Angel & 8 others	52/100
6th	RAYDIAX 2021, Magdeburg (Germany), Series A	Developer of therapy-assist CT system for minimally invasive interventions	$8.4M	Bmp Ventures, HTGF & 4 others	52/100
7th	NeoCura 2017, Changping (China), Series A	Provider of an AI-enabled immunotherapy based tumor diagnostic platform	$38.2M	CDH, PICC Capital Investment Management & 5 others	52/100
8th	Ferronova 2016, Salisbury (Australia), Series A	Provider of magnetic probe based device of treatment of multiple cancer	$17.5M	Uniseed, Renew Pharmaceuticals & 7 others	51/100
9th	Windtree Therapeutics 1992, Philadelphia (United States), Public	Developer of therapies for oncology and cardiovascular diseases with unmet needs	$45K	VMS Asset Management, Panacea Venture & 2 others	50/100
10th	Imagion Biosystems 2016, Albuquerque (United States), Public	Developer of molecular magnetic resonance imaging technology for cancer detection	-	Marbruck Investments, HHS & 1 others	50/100
117th	Oncoparse Melbourne (Australia), Unfunded	Developer of a non-invasive pancreatic cancer diagnostic tool	-	-	16/100